Feedback
Settings

Settings

Goto Application

3,654 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FPUGCISOLXNPPC-IOSLPCCCSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 366
1.WO/2025/240659ACTIVATABLE CONSTRUCTS, COMPOSITIONS AND METHODS
WO - 20.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/029426 Applicant CYTOMX THERAPEUTICS, INC. Inventor FOX, Ellaine Anne Mariano
Activatable constructs and methods of making and treating using the same, comprising a first antigen binding domain (AB1) having specific binding affinity for a first antigen, wherein the AB1 comprises a heavy chain variable domain 1 (HVD1) and a light chain variable domain 1 (LVD1), wherein the HVD1 is covalently coupled directly or indirectly to a first masking moiety (MM1) via a first cleavable moiety (CM1), wherein the LVD1 is covalently coupled directly or indirectly to a second masking moiety (MM2) via a second cleavable moiety (CM2), a second antigen binding domain (AB2) having specific binding affinity for a second antigen, wherein the AB2 comprises a heavy chain variable domain 2 (HVD2) and a light chain variable domain 2 (LVD2), a first dimerization domain (DD1) and a second dimerization domain (DD2).
2.WO/2025/240509LIGATION OF POLYNUCLEOTIDES BY LIGASES AND SCREENING METHODS THEREOF
WO - 20.11.2025
Int.Class C12Q 1/25
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
25involving enzymes not classifiable in groups C12Q1/26-C12Q1/7097
 Appl.No PCT/US2025/029185 Applicant CODEXIS, INC. Inventor BIMM, Alexander, Jacob
The present disclosure provides a method of predicting a reaction condition activity profile of a ligase for a ligase substrate by Gaussian Process Regression using activity data obtained for different reaction conditions. Further provided is a method of screening a plurality of ligases for activity on a ligase substrate for identifying ligases active on the ligase substrate.
3.WO/2025/237619RIBOSOMAL RNA FRAGMENT METHYLATION PATTERN INDICATIVE FOR LUNG CANCER
WO - 20.11.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/EP2025/060456 Applicant HUMMINGBIRD DIAGNOSTICS GMBH Inventor RAJAKUMAR, Timothy
The present invention relates to a method for diagnosing lung cancer in a patient by determining the methylation status of a ribosomal RNA (rRNA) fragment.
4.WO/2025/237620A COMPUTATIONAL METHOD FOR SMALL RNA BIOMARKER MODIFICATION CLASSIFICATION
WO - 20.11.2025
Int.Class G16B 20/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
20Allele or variant detection, e.g. single nucleotide polymorphism detection
 Appl.No PCT/EP2025/060457 Applicant HUMMINGBIRD DIAGNOSTICS GMBH Inventor RAJAKUMAR, Timothy
The present invention relates to a method classifying target RNA modifications in a neural network system, to a method for training a neural network system that is configured to classify target RNA modifications, to a neural network system, to a computer system adapted to classify target RNA modifications, to a computer program and to a non-transitory readable medium.
5.20250340907METHODS AND COMPOSITIONS FOR MODULATING A GENOME
US - 06.11.2025
Int.Class C12N 15/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
90Stable introduction of foreign DNA into chromosome
 Appl.No 19272711 Applicant Flagship Pioneering Innovations VI, LLC Inventor Anne Helen Bothmer

Methods and compositions for modulating a target genome are disclosed. This disclosure relates to novel compositions, systems and methods for altering a genome at one or more locations in a host cell, tissue or subject, in vivo or in vitro. In particular, the invention features compositions, systems and methods for inserting, altering, or deleting sequences of interest in a host genome.

6.WO/2025/228326RECOMBINANT RNA MOLECULE AND USE THEREOF
WO - 06.11.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/CN2025/091753 Applicant SHENZHEN SHENXIN BIOTECHNOLOGY CO., LTD. Inventor LI, Linxian
Provided are a recombinant RNA molecule and a use thereof. The recombinant RNA molecule comprises a polynucleotide encoding a polypeptide of interest and 5'-UTR and/or 3'-UTR. The recombinant RNA molecule has improved translation efficiency and/or stability; and the expression level of the polypeptide and/or protein is increased. Also provided are a vector encoding the recombinant RNA molecule, a pharmaceutical composition comprising the recombinant RNA molecule, and a method for treating or preventing a disease by using the recombinant RNA molecule.
7.WO/2025/231360NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME
WO - 06.11.2025
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
 Appl.No PCT/US2025/027494 Applicant MODERNATX, INC. Inventor AZMI, Ishara
The present disclosure provides novel CRISPR-associated (Cas) nucleases, as well as polynucleotides (e.g., DNA and RNA polynucleotides) encoding the same, host cells containing such nucleases and polynucleotides, and methods of using the foregoing compositions to effectuate genetic editing.
8.20250340863POLYPEPTIDE-ENCODED LIBRARY AND SCREENING METHOD USING SAME
US - 06.11.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No 18870952 Applicant WHOLESOME FUTURE LIMITED Inventor Haifeng ZHAO

A polypeptide-encoded nucleic acid or small molecule compound library includes polypeptide barcode tags and nucleic acid molecules or small molecule compounds corresponding to the polypeptide barcode tags. Further provided is a polypeptide-encoded nucleic acid or small molecule compound library, the library comprising a plurality of beads, and each bead comprising a polypeptide barcode tag connected to the bead and a nucleic acid molecule or a small molecule compound corresponding to the polypeptide barcode tag. A method is for screening a target nucleic acid or small molecule via the polypeptide-encoded nucleic acid or small molecule compound library. A screened nucleic acid molecule or small molecule compound is identified by decoding a polypeptide barcode tag associated therewith.

9.20250340877RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of Use
US - 06.11.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 19188473 Applicant Arrowhead Pharmaceuticals, Inc. Inventor Jeffrey Carlson

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof. The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.

10.WO/2025/229953METHOD FOR PRODUCING OLIGONUCLEOTIDE
WO - 06.11.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No PCT/JP2025/016225 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor MIYAGAWA, Takuya
The purpose of the present invention is to provide a method for efficiently producing an oligonucleotide by a solid-phase synthesis approach. The present invention provides a method for producing an oligonucleotide by a solid phase synthesis approach, the method comprising a step for reacting an oligonucleotide in which a hydroxyl group at a chain extendable end is protected with a protective group that can be removed under acidic conditions and a deblocking solution to remove a protective group for a hydroxyl group at the chain extendable end, wherein the deblocking solution is a deblocking solution containing a base, an acid, and an aprotic solvent, and the base is a base having an acid dissociation constant (pKa) of a conjugate acid of 5-12, and an oligonucleotide in which the content ratio of the 2', 3'transfer body is a certain amount or less.
# -